XPH

State Street SPDR S&P Pharmaceuticals ETF

Investor Moves

Name	Value	Action	Change	Price	Current Price
Ken GriffinCitadel Advisors $-4.3M ExitQ1 2026 $4.3M -- $58.49
Ken GriffinCitadel Advisors $4.3M76.4k shares AddQ4 2025 $4.0M $56.01 $58.49
Ken GriffinCitadel Advisors $-1.2M TrimQ3 2025 $1.2M -- $58.49
Ken GriffinCitadel Advisors $1.1M AddQ2 2025 $1.1M -- $58.49
Ken GriffinCitadel Advisors $-2.3M TrimQ1 2025 $2.3M -- $58.49
Ken GriffinCitadel Advisors $1.1M AddQ4 2024 $1.1M -- $58.49

News

zacks.comIs State Street SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?zacks.comJun 5

fool.comState Street SPDR S&P Pharmaceuticals vs First Trust NYSE Arca Biotech: Which Is the Better ETF For Your Portfolio?fool.comJun 4

fool.comBiotech ETFs: Which ETF Offers Lower Fees? IBBQ or XPH?fool.comJun 4

zacks.comShould You Invest in the State Street SPDR S&P Pharmaceuticals ETF (XPH)?zacks.comJun 3

247wallst.comDitch or Double Down on This Pharma ETF as Trump Adjusts Drug Prices?247wallst.comMay 19

Trade XPH

About State Street SPDR S&P Pharmaceuticals ETF

The State Street SPDR S&P Pharmaceuticals ETF aims to deliver investment results that closely correspond to the total return of the S&P Pharmaceuticals Select Industry Index, prior to accounting for fees and expenses. It offers investors focused access to the pharmaceuticals segment, specifically the Pharmaceuticals sub-industry as classified by the S&P Total Market Index. By tracking a modified equal-weighted index, the fund ensures a balanced industry exposure across companies of various sizes, including large, mid, and small-cap stocks, thereby mitigating concentration risk. This design provides a more granular approach, empowering investors to adopt strategic or tactical positions within the pharmaceutical sector with greater specificity than traditional, broader sector-based investment vehicles.

IPO Date: Jun 22, 2006

Market Data

Open: $61.46
High: $61.46
Low: $60.17
Volume: 35.4K
Avg Volume: 50K
52W High: $61.46
52W Low: $40.26

Valuation

Market Cap: $246M
Dividend Yield: 37.2%

Financials

Financial statement snapshot is not available yet.

Events

DividendJun 22

$0.059045